Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer, Angelique; Maes, Ken; Herviou, Laurie; Kassambara, Alboukadel; Seckinger, Anja; Cartron, Guillaume; Rème, Thierry; Robert, Nicolas; Requirand, Guilhem; Boireau, Stéphanie; Müller-Tidow, Carsten; Veyrune, Jean-Luc; Vincent, Laure; Bouhya, Salahedine; Goldschmidt, Hartmut; Vanderkerken, Karin; Hose, Dirk; Klein, Bernard; De Bruyne, Elke; Moreaux, Jerome.
Br J Cancer; 118(8): 1062-1073, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29500406

BACKGROUND:

Multiple myeloma (MM) is the second most common hematologic malignancy. Aberrant epigenetic modifications have been reported in MM and could be promising therapeutic targets. As response rates are overall limited but deep responses occur, it is important to identify those patients who could indeed benefit from epigenetic-targeted therapy.

METHODS:

Since HDACi and DNMTi combination have potential therapeutic value in MM, we aimed to build a GEP-based score that could be useful to design future epigenetic-targeted combination trials. In addition, we investigated the changes in GEP upon HDACi/DNMTi treatment.

RESULTS:

We report a new gene expression-based score to predict MM cell sensitivity to the combination of DNMTi/HDACi. A high Combo score in MM patients identified a group with a worse overall survival but a higher sensitivity of their MM cells to DNMTi/HDACi therapy compared to a low Combo score. In addition, treatment with DNMTi/HDACi downregulated IRF4 and MYC expression and appeared to induce a mature BMPC plasma cell gene expression profile in myeloma cell lines.

CONCLUSION:

In conclusion, we developed a score for the prediction of primary MM cell sensitivity to DNMTi/HDACi and found that this combination could be beneficial in high-risk patients by targeting proliferation and inducing maturation.
Selo DaSilva